[1] Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, et al. On the safety 5-[125I]iodo-2-deoxy-uridine preclinical evaluation in swine[J]. Acta Oncol, 1996, 35(7):925-933.
[2] Taverna P, Hwang HS, Schupp JE, et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced eytotoxicity and radiosensitization[J]. Cancer Res, 2003, 63(4):838-846.
[3] Yan T, Seo Y, Schupp JE, et al. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther, 2006, 5(4):893-902.
[4] Dupertuis YM, Xiao WH, De Tribolet N, et al. Unlabeled iododeoxyuridine increase the rate of uptake of[125] iododeoxyuridine in human xenografted glioblastomas[J]. Eur J Nucl Med Mol Imaging, 2002, 29(4):499-505.
[5] Howell RW, Bishayee A. Bystander effects caused by nonuniform distributions of DNA-incorporated(125)I[J]. Micron, 2002, 33(2):127-132.
[6] Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo[J]. Proc Nat Acad Sci USA, 2002, 99(21):13765-13770.
[7] Kassis AI, Wen PY, Van den Abbeele AD, et al. 5-[125I]iodo-2-deoxyuridine in the of brain radiotherapy tumors in rats[J]. J Nucl Med, 1998, 39(7):1148-1154.
[8] Kassis AI, Dahman BA, Adalstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-2-deoxyuridine[J]. Acta Oncol, 2000, 39(6):731-737.
[9] Galanis E, Goldberg R, Reid J, et al. Phase Ⅰ trial of sequential administration of raltitrexed(Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd)[J]. Ann Oncol, 2001, 12(5):701-707.
[10] Dupertuis YM, Vazquez M, Mach JP, et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine[J]. Cancer Res, 2001, 61(21):7971-7977.
[11] Seo Y, Yan T, Schupp JE, et al. The interaction between two radiosensitizers:5-iododeoxyuridine and caffeine[J]. Cancer Res, 2006, 66(1):490-498.
[12] 马晓东,Dillehay LE,Williams JR,et al.局部缓释125I-UdR治疗恶性星形细胞瘤实验研究[J].中华神经外科疾病研究杂志,2005,4(4):293-298.
[13] Malrs RJ, Wideman CL, Angerson WJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model[J]. Br J Cancer, 2000, 82(1):74-80.
[14] Kinsella TJ, Vielhuber KA, Kunugi KA, et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyufidine radiosensitization in U251 human glioblastoma xenografts[J]. Clin Cancer Res, 2000, 6(4):1468-1475.
[15] Harrington K J, Syrigos KN, Uster PS, et al. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xneograft model[J]. Br J Cancer, 2004, 91(2):366-373.
[16] Semnani ES, Wang K, Adelstein SJ, et al. 5-[123I/125I]iodo-2-deoxyuridine in metastatic lung cancer:radiopharmaceutical formulation affects targeting[J]. J Nucl Med, 2005, 46(5):800-806.
[17] Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, et al. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer[J]. J Urology, 1999, 162(1):58-62.
[18] Macapinlac HA, Kemeny N, Daghighian F, et al. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver[J]. J Nucl Med, 1996, 37(4 suppl):25s-29s.
[19] Ou XH, Kuang AR, Peng X, et al. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy[J]. World J Gastroenterol, 2003, 9(8):1675-1678.